IRIS
FAGGIANO, ANTONGIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.484
NA - Nord America 6.922
EU - Europa 5.293
SA - Sud America 994
AF - Africa 221
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 21.927
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.666
SG - Singapore 3.803
RU - Federazione Russa 2.611
VN - Vietnam 1.623
CN - Cina 1.597
BR - Brasile 801
HK - Hong Kong 721
IT - Italia 657
DE - Germania 403
FR - Francia 292
FI - Finlandia 237
NL - Olanda 233
SE - Svezia 193
GB - Regno Unito 168
CA - Canada 164
IE - Irlanda 145
UA - Ucraina 138
IN - India 131
JP - Giappone 121
AR - Argentina 78
CI - Costa d'Avorio 74
KR - Corea 74
BD - Bangladesh 59
MX - Messico 59
ZA - Sudafrica 58
PL - Polonia 56
IQ - Iraq 53
PH - Filippine 42
TH - Thailandia 35
ID - Indonesia 34
TR - Turchia 29
EC - Ecuador 27
ES - Italia 27
BE - Belgio 23
PK - Pakistan 22
AT - Austria 20
CO - Colombia 20
VE - Venezuela 20
CZ - Repubblica Ceca 17
TW - Taiwan 17
LT - Lituania 16
JO - Giordania 15
CL - Cile 14
EG - Egitto 14
MA - Marocco 14
UZ - Uzbekistan 14
PY - Paraguay 12
DZ - Algeria 9
KE - Kenya 9
PE - Perù 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
KZ - Kazakistan 8
NP - Nepal 8
CH - Svizzera 7
ET - Etiopia 7
MY - Malesia 7
OM - Oman 7
PT - Portogallo 7
RS - Serbia 7
AZ - Azerbaigian 6
HU - Ungheria 6
AU - Australia 5
IL - Israele 5
LB - Libano 5
MN - Mongolia 5
NI - Nicaragua 5
PA - Panama 5
SA - Arabia Saudita 5
SN - Senegal 5
SY - Repubblica araba siriana 5
UY - Uruguay 5
AL - Albania 4
BA - Bosnia-Erzegovina 4
DO - Repubblica Dominicana 4
GH - Ghana 4
HR - Croazia 4
JM - Giamaica 4
CR - Costa Rica 3
EU - Europa 3
HN - Honduras 3
KW - Kuwait 3
MD - Moldavia 3
MZ - Mozambico 3
NG - Nigeria 3
PS - Palestinian Territory 3
TJ - Tagikistan 3
AM - Armenia 2
BG - Bulgaria 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GT - Guatemala 2
IR - Iran 2
KG - Kirghizistan 2
NC - Nuova Caledonia 2
NO - Norvegia 2
Totale 21.894
Salva come PNG Salva come JPEG
Città #
Singapore 1.814
San Jose 1.286
Hong Kong 705
Chandler 677
Moscow 656
Ashburn 567
Beijing 503
Ho Chi Minh City 473
Hanoi 353
Santa Clara 299
Hefei 267
Amsterdam 214
Millbury 201
The Dalles 187
Lauterbourg 185
Los Angeles 171
Princeton 155
Nanjing 144
Munich 140
Naples 116
Jacksonville 115
Napoli 113
Tokyo 105
New York 97
Buffalo 88
São Paulo 86
Redondo Beach 80
Des Moines 76
Wilmington 75
Boston 73
Ottawa 71
Haiphong 70
Frankfurt am Main 62
Da Nang 61
Helsinki 57
Dallas 53
Orem 52
Turku 52
Seattle 48
Warsaw 45
Council Bluffs 43
Chicago 42
Houston 42
Seoul 42
Denver 36
Milan 36
Brooklyn 35
Rome 35
Chennai 34
London 34
Atlanta 33
Nanchang 33
Hebei 32
Düsseldorf 31
Biên Hòa 30
Johannesburg 29
Montreal 29
Falkenstein 28
Poplar 28
Ann Arbor 27
Stockholm 27
Lawrence 26
Nuremberg 26
Toronto 26
Mexico City 25
Shenyang 25
Dong Ket 24
Kochi 22
Tianjin 22
Hải Dương 21
Phoenix 21
Rio de Janeiro 21
Manchester 20
San Francisco 19
Belo Horizonte 17
Can Tho 17
Dhaka 17
Washington 17
Woodbridge 17
Jiaxing 16
Norwalk 16
Kunming 15
Mumbai 15
Amman 14
Boardman 14
Courcelles 14
Dublin 14
Brasília 13
Bắc Giang 13
Campinas 13
Changsha 13
Ninh Bình 13
Porto Alegre 13
Quito 13
Thái Nguyên 13
Charlotte 12
Kronberg 12
Lahore 12
Paris 12
Roubaix 12
Totale 11.963
Salva come PNG Salva come JPEG
Nome #
Endocrine dysfunction in patients with Fabry disease 185
Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. 185
Emerging therapies in pheochromocytoma and paraganglioma: Immune checkpoint inhibitors in the starting blocks 180
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease 177
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. 162
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 159
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 159
GLP-1: benefits beyond pancreas. 156
Hepatic arterial embolization in patients with neuroendocrine tumors. 156
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR 155
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 155
Open issues on G3 neuroendocrine neoplasms: Back to the future 152
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 152
Quality of life in patients with neuroendocrine neoplasms: The role of severity, clinical heterogeneity and resilience 152
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 150
Bone metastases in neuroendocrine neoplasms: From pathogenesis to clinical management 150
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors 149
The evolving field of kinase inhibitors in thyroid cancer. 147
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 147
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms 143
Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? 142
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 141
HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy 141
A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy 140
Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules 140
Cushing's syndrome: aftermath of the cure. 139
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm 136
A rare rarity: Neuroendocrine tumor of the esophagus 135
Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. 135
Diagnosis of Flier’s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature 135
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1 134
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. 133
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features 132
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study 132
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. 131
Nutrition and neuroendocrine tumors: An update of the literature. 131
Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas 129
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors 129
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission 128
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure 128
Thyroid function in Fabry disease before and after enzyme replacement therapy. 126
Limitations of Chromogranin A in clinical practice. 125
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1 125
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 125
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies (Oct, 10.1007/s40618-022-01905-4, 2022) 124
Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame 124
Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome 123
Impairment of bone status in patients with central diabetes insipidus 123
Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors 122
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers 121
INFLUENCE OF NUTRITION ON HPA AXIS AND BODY COMPOSITION: EFFECT OF 30-DAY MODERATELY HYPOCALIRIC DIET HIGH-PROTEIN IN OBESE FEMALE SUBJECTS 121
Ketogenic diet: a tool for the management of neuroendocrine neoplasms? 121
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients 120
Insulin resistance and acne: a new risk factor for men? 120
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. 120
Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors 120
The safety of available treatments options for neuroendocrine tumors 120
An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma 120
Vitamin D and cancer. 119
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 119
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery 118
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumors. 118
The management of neuroendocrine tumours: A nutritional viewpoint 118
Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? 117
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 117
Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? 117
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature 117
Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study 116
The roles of parathyroid hormone in bone remodeling. prospects for novel therapeutics 115
Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: The two-faced Janus 115
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study 114
Role of Metformin on Recurrence-Free Survival in Neuroendocrine Tumors 113
Thyroid nodules and related symptoms are stably controlled two years afterradiofrequency thermal ablation. 113
Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1 113
Gestione integrata del tumore della prostata: il ruolo dell’endocrinologo 112
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. 112
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. 112
Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences 112
Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study 111
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration 111
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D-2 receptor scintigraphy 111
Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer 111
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib 111
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline 110
Nuove strategie terapeutiche per il trattamento dei NET 109
Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease 109
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure 109
Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma 109
Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target 109
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus 108
Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration 108
Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism 108
Tumori neuroendocrini 108
Diagnosis and differential diagnosis of MTC. 108
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature 108
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons 107
Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery 107
Risk factors for gastroenteropancreatic neuroendocrine neoplasms ({GEP}-{NENs}): a three-centric case{\textendash}control study 106
Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease 106
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. 106
Totale 12.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.175
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.175
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 0 0 0 0 16 34 34
2021/20221.063 13 1 32 5 22 97 3 33 158 69 234 396
2022/20231.563 191 137 38 141 192 165 44 131 214 208 82 20
2023/2024970 41 140 126 76 58 88 43 119 7 20 161 91
2024/20255.887 265 286 47 37 157 362 620 409 403 629 2.129 543
2025/202611.169 1.210 878 1.113 1.087 2.101 407 1.434 718 1.587 634 0 0
Totale 22.225